With the acquisition of LEX Diagnostics now complete, QuidelOrtho achieves a critical milestone in its strategy to accelerate growth in point-of-care molecular testing – one of the fastest-growing segments in the global diagnostics market.

The LEX VELO System is a breakthrough molecular diagnostics platform designed to deliver highly sensitive, multiplex PCR testing for Influenza A, Influenza B and COVID-19 directly from a swab sample. Its proprietary cartridge-based design supports rapid clinical decision-making in decentralized care environments by eliminating the need for external liquid handling, delivering speed, reliability and ease of use with results in approximately six to ten minutes.

The LEX VELO System received U.S. Food and Drug Administration (“FDA”) 510(k) clearance and CLIA waiver in February 2026. U.S. commercial launch is expected later this year. 

Learn more about the acquisition and the LEX VELO testing platform here.

For more information about QuidelOrtho, contact us.